Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis

Next Previous
Search
Trial Profile

Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SHR 6508 (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Pharmacokinetics
  • Sponsors Shanghai Hengrui Pharmaceutical

    • Most Recent Events

    • 07 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 04 Jul 2023 Planned End Date changed from 30 Sep 2022 to 1 Aug 2023.
    • 04 Jul 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top